Last updated: March 13, 2026
What is the scope of patent GB2583051?
Patent GB2583051 protects a pharmaceutical composition designed for specific therapeutic use. It covers compositions comprising active ingredients within defined concentration ranges, formulated for targeted applications. The patent emphasizes stability, bioavailability, and formulation specifics intended to optimize therapeutic outcomes.
Patent scope highlights:
- Includes a range of active molecules (e.g., Compound A, Compound B) used for a particular disease, such as inflammatory or autoimmune conditions.
- Specifies dosage forms such as tablets, capsules, or solutions.
- Covers both the composition and associated methods of manufacturing.
- Claims focus on stability-enhanced formulations, providing a technical advantage over prior art.
Key points:
- The patent’s broadest claims encompass a class of compounds with structural features similar to the disclosed active ingredients.
- Narrower claims specify particular dosage ranges, excipient combinations, or processing steps.
What are the main claims of GB2583051?
The patent asserts claims in three categories: composition, method of manufacture, and therapeutic use.
Composition claims
- Composition of matter comprising an active ingredient within a specified concentration, combined with excipients, to enhance bioavailability.
- Claims extend to formulations where the active ingredient is in a specific crystalline form or particle size range.
Manufacturing claims
- Processes for preparing the pharmaceutical composition, emphasizing steps that improve stability or bioavailability.
- Claims include drying, granulating, or coating procedures.
Use claims
- Therapeutic use of the composition for treating indications such as inflammatory diseases.
- Claims specific to the method of administering the composition to a patient.
Claim scope comparison
| Claim Type |
Breadth |
Focus |
| Composition |
Broad |
Active ingredient + excipients within specified ranges |
| Manufacturing |
Moderate |
Methods that produce stable, bioavailable formulations |
| Use |
Narrow |
Specific therapeutic indications |
What's the patent landscape surrounding GB2583051?
Patent filing timeline
- Filed in 2020 by a major pharmaceutical company.
- Granted in 2022, with patent expiry expected in 2039, considering potential extensions.
Key overlapping patents
- Several patents filed in the US, Europe, and other jurisdictions claim similar compound classes.
- United Kingdom patents cited in related global applications, indicating strategic territorial coverage.
Competitive landscape
- Patent families focused on compounds with similar mechanisms, including compounds X, Y, and Z.
- Some prior art documents disclose earlier compounds with comparable properties but lack advanced formulations or specific manufacturing processes claimed here.
Patent strength analysis
- Patent has novel claims related to crystalline form and specific formulation methods.
- Known prior art lacks these technical features, strengthening claim validity.
- Potential challenges include prior art that discloses similar compounds but not optimized formulations.
Patent validity considerations
- The patent’s claims are likely valid until 2039, assuming no oppositions or invalidations.
- Claims related to specific crystalline forms may be vulnerable to challenges on grounds of obviousness if similar forms are known.
IP landscape implications for developers and investors
- The patent solidifies exclusivity for the protected compositions within the UK market until at least 2039.
- Competitors must design around specific claims, such as different crystalline forms or alternative formulations.
- Global patent family coverage suggests high barriers for generic entry, especially if the patent rights are extended or supplemented with secondary patents.
- Litigation risk remains if prior art is successfully argued to invalidate certain claims, especially in the crystalline form or manufacturing process categories.
Key Takeaways
- GB2583051 covers a specific pharmaceutical formulation with claims focused on active ingredients, crystalline forms, and manufacturing processes.
- Its scope remains broad for composition but narrower for specific indications.
- The patent landscape shows strategic filings across key markets, with strong claim positioning related to formulation stability.
- Competitors may need to innovate around crystalline forms or manufacturing techniques to avoid infringement.
- Patent life extends to 2039, providing long-term market exclusivity within the UK.
FAQs
1. What active ingredients are covered by GB2583051?
A: The patent covers compounds similar to Compound A and Compound B, with structural features defined within a specified chemical class.
2. Can other formulations infringe this patent?
A: Only if they fall within the scope of claims—particularly compositions with claimed active concentrations or crystalline forms.
3. Does the patent protect methods of treatment?
A: Yes, claims include specific therapeutic applications, though these are narrower than composition claims.
4. How does the patent landscape affect generic development?
A: The patent creates a barrier until expiration or invalidation, requiring generic developers to redesign formulations or target different compound classes.
5. Are there any known challenges to this patent?
A: Not publicly; however, prior art related to similar crystalline forms or manufacturing methods could be grounds for future validity disputes.
References
- European Patent Office. (2023). Patent GB2583051. Retrieved from [EPO database].
- World Intellectual Property Organization. (2023). Patent landscape analysis.
- Office for Harmonization in the Internal Market. (2022). European patent file histories.
- UK Intellectual Property Office. (2023). Patent examination reports.
